chimeric monoclonal antibody F2 of anti-human platelet glycoprotein IIb/IIIa (Suzhou Dixing Biomedical Technology)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namechimeric monoclonal antibody F2 of anti-human platelet glycoprotein IIb/IIIa (Suzhou Dixing Biomedical Technology)
Drug Alias NamePulaimab
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionPlatelet aggregation inhibitors
TargetsUpdating
Therapy Area/IndicationsThrombosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsThrombosis

Other Information

ATC CodeN/A
Related LinksN/A